Shares of Teledyne Technologies plunged 11.2% to $605.64 on August 12, erasing roughly $3.6 billion in market value after the company announced it would acquire Varex Imaging Corporation in a $1.1 billion all-cash deal. Varex stockholders will receive $18.90 per share, representing a 52.3% premium from the stock's last close. The sell-off signals Wall Street's skepticism that Teledyne is getting a bargain — and it lands on a jittery day with the August CPI inflation report looming.
A Rich Premium for a Slow-Growth Business. Varex generates roughly $858 million in trailing twelve-month revenue, and its fiscal 2025 annual revenue of $844.6 million grew just 4.1% year-over-year — well behind the medical-device industry average. Teledyne is paying 9.25 times Varex's EBITDA (earnings before interest, taxes, and non-cash charges — a common yardstick for what a business actually earns from operations). For a company with a 34.2% gross margin and a thin 7.3% operating margin , that valuation demands meaningful cost savings to justify itself.
All Cash Means More Leverage on an Already-Expensive Stock. Before the deal, Teledyne traded at a 33.4x trailing price-to-earnings ratio on $6.37 billion in revenue , with roughly $340 million in cash on hand. Writing a $1.1 billion check will likely require new borrowing, increasing debt at a time when interest rates remain elevated. That directly pressures future earnings per share and explains the sharp markdown.
Strategic Logic Exists, But Execution Risk Is High. Teledyne highlights the complementarity of Varex's X-ray sources and detectors with its existing digital imaging and vacuum electronics businesses.
Teledyne already has a significant healthcare imaging footprint through prior acquisitions and serves many of the same customers as Varex with complementary technologies. The fit makes industrial sense — bundling X-ray tubes and digital detectors alongside Teledyne's sensors and cameras. But Varex's margins are well below Teledyne's 43.3% gross margin, meaning integration must lift profitability or the deal will drag on overall returns.
The Timing Adds Uncertainty. The transaction is expected to close in early 2027, subject to shareholder and regulatory approvals , leaving months of execution limbo. Varex also received $17 million in tariff refunds last quarter, booking a $10 million gross-profit boost that flatters recent results. Investors will need to see whether Varex's underlying earnings hold without one-time tailwinds before this deal pencils out.